Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesús M. Bañales, José J.G. Marı́n, Ángela Lamarca, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 9, pp. 557-588
Open Access | Times Cited: 1685

Showing 1-25 of 1685 citing articles:

Cholangiocarcinoma
Paul J. Brindley, Melinda Bachini, Sumera I. Ilyas, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 490
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation
Andrew X. Zhu, Teresa Macarulla, Milind Javle, et al.
JAMA Oncology (2021) Vol. 7, Iss. 11, pp. 1669-1669
Open Access | Times Cited: 332
Cancer-associated fibroblasts in the single-cell era
Dor Lavie, Aviad Ben‐Shmuel, Neta Erez, et al.
Nature Cancer (2022) Vol. 3, Iss. 7, pp. 793-807
Open Access | Times Cited: 322
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Milind Javle, Sameek Roychowdhury, Robin Kate Kelley, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 10, pp. 803-815
Closed Access | Times Cited: 308
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Arndt Vogel, John Bridgewater, Julien Edeline, et al.
Annals of Oncology (2022) Vol. 34, Iss. 2, pp. 127-140
Open Access | Times Cited: 307
Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 3, pp. 228-239
Open Access | Times Cited: 305
Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations
Silvia Affò, Ajay Nair, Francesco Brundu, et al.
Cancer Cell (2021) Vol. 39, Iss. 6, pp. 866-882.e11
Open Access | Times Cited: 267
The implications of IDH mutations for cancer development and therapy
Christopher J. Pirozzi, Hai Yan
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 10, pp. 645-661
Closed Access | Times Cited: 247
Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma
Liangqing Dong, Dayun Lu, Ran Chen, et al.
Cancer Cell (2021) Vol. 40, Iss. 1, pp. 70-87.e15
Closed Access | Times Cited: 222
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Laura Izquierdo‐Sánchez, Ángela Lamarca, Adelaida La Casta, et al.
Journal of Hepatology (2022) Vol. 76, Iss. 5, pp. 1109-1121
Open Access | Times Cited: 214
Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids
Ary Marsee, Floris J.M. Roos, Monique M.A. Verstegen, et al.
Cell stem cell (2021) Vol. 28, Iss. 5, pp. 816-832
Open Access | Times Cited: 211
Lipid alterations in chronic liver disease and liver cancer
Bichitra Paul, Monika Lewińska, Jesper B. Andersen
JHEP Reports (2022) Vol. 4, Iss. 6, pp. 100479-100479
Open Access | Times Cited: 189
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
Christopher L. Bowlus, Lionel Arrivé, Annika Bergquist, et al.
Hepatology (2022) Vol. 77, Iss. 2, pp. 659-702
Open Access | Times Cited: 161
Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma
Guangyu Ding, Jiaqiang Ma, Jing‐Ping Yun, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 3, pp. 608-618
Closed Access | Times Cited: 138
Targeting FGFR inhibition in cholangiocarcinoma
Lipika Goyal, Sarinya Kongpetch, Valerie Crolley, et al.
Cancer Treatment Reviews (2021) Vol. 95, pp. 102170-102170
Open Access | Times Cited: 135
Novel therapeutic targets for cholestatic and fatty liver disease
Michael Trauner, Claudia Fuchs
Gut (2021) Vol. 71, Iss. 1, pp. 194-209
Open Access | Times Cited: 129
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study
John Bridgewater, Peter Fletcher, Daniel H. Palmer, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 18, pp. 2048-2057
Open Access | Times Cited: 128
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
Domenico Alvaro, Gregory J. Gores, Joël Walicki, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 1, pp. 181-208
Open Access | Times Cited: 126
Cholangiocarcinoma
Samantha Sarcognato, Diana Sacchi, Matteo Fassan, et al.
Pathologica (2021) Vol. 113, Iss. 3, pp. 158-169
Open Access | Times Cited: 122
Harnessing Nanomaterials for Cancer Sonodynamic Immunotherapy
Shuang Liang, Jianjun Yao, Dan Liu, et al.
Advanced Materials (2023) Vol. 35, Iss. 33
Closed Access | Times Cited: 122
CAFs shape myeloid‐derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5‐lipoxygenase
Yuli Lin, Qian Cai, Yu Chen, et al.
Hepatology (2021) Vol. 75, Iss. 1, pp. 28-42
Closed Access | Times Cited: 119
Fluorescence image-guided tumour surgery
Kun Wang, Yang Du, Zeyu Zhang, et al.
Nature Reviews Bioengineering (2023) Vol. 1, Iss. 3, pp. 161-179
Closed Access | Times Cited: 106
Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma
Chiara Raggi, Maria Letizia Taddei, Elena Sacco, et al.
Journal of Hepatology (2021) Vol. 74, Iss. 6, pp. 1373-1385
Open Access | Times Cited: 103
Current epidemiology of cholangiocarcinoma in Western countries
Mathew Vithayathil, Shahid A. Khan
Journal of Hepatology (2022) Vol. 77, Iss. 6, pp. 1690-1698
Closed Access | Times Cited: 102
Metabolic reprogramming in cholangiocarcinoma
Chiara Raggi, Maria Letizia Taddei, Colin Rae, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 3, pp. 849-864
Open Access | Times Cited: 97
Page 1 - Next Page

Scroll to top